Skip to main content
Clinical Trials/NL-OMON33283
NL-OMON33283
Recruiting
Phase 4

Evaluation of cognitive function of patients treated with sunitinib or sorafenib (UMCONCO200904 - Evaluation of cognitive function of patients with sunitinib or sorafenib

niversitair Medisch Centrum Sint Radboud0 sites80 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
GIST
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
80
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • \-patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or
  • Sorafenib for \>\= 8 weeks
  • \- Karnofsky score \> 70%
  • \- age \> 18 year.
  • \- written informed consent for study;Healthy controls selection:
  • \-Healthy individuals:
  • \- Karnofsky score \> 70%
  • \- age \> 18 year
  • \- written informed consent for study;Patient controls selection
  • \-patients with metastastic renal cell cancer or GIST who aren\*t treated yet (only interferon alfa or interleukine 2 treatment is allowed when \> 12 months ago.

Exclusion Criteria

  • \- contra\-indications for treatment with Sunitinib or Sorafenib
  • \- patients who do not speak or write the Dutch language adequately
  • \- known brain metastasis
  • \- use of psychiatric or anti\-epileptic medication
  • \- known cognitive disorders unrelated to diagnosis or medication use
  • \- radiotherapy on the brain at any time in the past
  • \- systemic chemotherapy
  • \- in the last 12 months interferon alfa or interleukine\-2 treatment
  • \- operation in the last 6 months
  • \- Diabetes Mellitus

Outcomes

Primary Outcomes

Not specified

Similar Trials